Oral SERD Tops Fulvestrant for PFS in ER-Positive Breast Cancer

Camizestrant also led to meaningful PFS improvements in those with detectable <em>ESR1</em> mutations

Related Keywords

Long Island ,Texas ,United States ,San Antonio ,Dallas ,University Of Texas Southwestern Medical Center ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Carlos Arteaga ,Mafalda Oliveira ,Hebron University Hospital ,Perlmutter Cancer Center ,San Antonio Breast Cancer ,Texas Southwestern Medical Center ,Medpage Today ,Douglas Marks ,Hospital Long Island ,Antonio Breast Cancer ,